PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-7.66%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 1.49%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-35.70%
Negative gross profit growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
20.21%
EBIT growth of 20.21% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see a marginal edge that could be expanded upon.
20.21%
Operating income growth of 20.21% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand.
113.92%
Net income growth of 113.92% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see potential if moderate gains can keep rising.
99.57%
EPS growth of 99.57% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
99.57%
Diluted EPS growth of 99.57% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could improve over time.
2.42%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.42%
Diluted share change of 2.42% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
81.64%
OCF growth of 81.64% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest positive difference, which can compound over time.
77.49%
FCF growth of 77.49% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
594.48%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 14.01%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
323.94%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 6.86%. Joel Greenblatt might see a short-term competitive advantage at play.
-161.58%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-776.11%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-559.39%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 9.03%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
284.96%
Net income/share CAGR of 284.96% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
43.41%
Net income/share CAGR of 43.41% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-93.73%
Negative 3Y CAGR while Drug Manufacturers - Specialty & Generic median is 15.10%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
5088.46%
Equity/share CAGR of 5088.46% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
710.77%
5Y equity/share CAGR of 710.77% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
47.80%
3Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 6.43%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.47%
AR shrinking while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-7.35%
Decreasing inventory while Drug Manufacturers - Specialty & Generic is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-3.72%
Assets shrink while Drug Manufacturers - Specialty & Generic median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-0.42%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -0.06%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.47%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-34.39%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
-20.17%
SG&A decline while Drug Manufacturers - Specialty & Generic grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.